Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins.
Drug Deliv
; 25(1): 1950-1962, 2018 Nov.
Article
in En
| MEDLINE
| ID: mdl-30799657
ABSTRACT
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and some side effects. To overcome such challenges, here we review the genetic engineering of the envelope glycoproteins for oHSVs to target tumors specifically, and at the same time we summarize the many neutralization antibodies against the envelope glycoproteins and align the neutralization epitopes with functional domains of the respective glycoproteins for future identification of new functions of the glycoproteins and future engineering of the epitopes to escape from host neutralization.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Glycoproteins
/
Protein Engineering
/
Viral Envelope Proteins
/
Simplexvirus
/
Oncolytic Virotherapy
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Drug Deliv
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2018
Document type:
Article
Affiliation country:
China